The dysfunction in how Australia and New Zealand approach pharmaceutical reimbursement is not just procedural. It is rooted in how these systems think about themselves and the myths that sustain their authority. For years, debates over these programs have been channelled into technical terrain that the institution controls and comfortably defends. Institutions shield themselves through their own mythology, recasting policy choices as unquestionable truths. Real reform depends on challenging those myths and exposing the political decisions they conceal.
Process as power - how our institutions defend policy decisions by making them untouchable truths
October 30, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News

